高山，東南大學(xué)，首席教授，博導(dǎo)
辦公地點(diǎn)：東南大學(xué)科技產(chǎn)業(yè)園（棲霞區(qū)）高等研究院
個(gè)人簡(jiǎn)介：
英國(guó)牛津大學(xué)醫(yī)學(xué)腫瘤學(xué)博士，先后在牛津和劍橋大學(xué)從事科研工作。主要研究方向聚焦在腫瘤驅(qū)動(dòng)突變及其表觀調(diào)控和免疫逃逸機(jī)制研究。以通訊作者在Proc Natl Acad Sci U S A（3篇）、Nature Communications、Journal Experimental Medicine、Science Advances、Cancer Research（2篇）、Cell Reports等雜志發(fā)表30多篇論文。公開(kāi)專(zhuān)利19項(xiàng)（包括三個(gè)國(guó)際PCT），獲得授權(quán)9個(gè)（包括國(guó)際PCT專(zhuān)利一項(xiàng)）。
研究方向：
腫瘤驅(qū)動(dòng)突變、表觀調(diào)控和分子機(jī)理；
藥物機(jī)理和生物標(biāo)志物
腫瘤免疫治療技術(shù)和分子機(jī)理
代表文章（均為最后/唯一通訊作者）
1. Pan, Y., Gu, Y., Liu, T., Zhang, Q., Yang, F., Duan, L., Cheng, S., Zhu, X., Xi, Y., Chang, X., Ye, Q. & Gao, S. Epitranscriptic regulation of HRAS by N(6)-methyladenosine drives tumor progression. Proceedings of the National Academy of Sciences of the United States of America 120, e2302291120, doi:10.1073/pnas.2302291120 (2023).
2. Yang, X., Wen, Y., Liu, S., Duan, L., Liu, T., Tong, Z., Wang, Z., Gu, Y., Xi, Y., Wang, X., Luo, D., Zhang, R., Liu, Y., Wang, Y., Cheng, T., Jiang, S., Zhu, X., Yang, X., Pan, Y., Cheng, S., Ye, Q., Chen, J*., Xu, X*. & Gao, S*. LCDR regulates the integrity of lysosomal membrane by hnRNP K-stabilized LAPTM5 transcript and promotes cell survival. Proceedings of the National Academy of Sciences of the United States of America 119, doi:10.1073/pnas.2110428119 (2022).
3. Wang, X., Yang, X., Zhang, C., Wang, Y., Cheng, T., Duan, L., Tong, Z., Tan, S., Zhang, H., Saw, P. E., Gu, Y., Wang, J., Zhang, Y., Shang, L., Liu, Y., Jiang, S., Yan, B., Li, R., Yang, Y., Yu, J., Chen, Y., Gao, G. F*., Ye, Q. & Gao, S. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proceedings of the National Academy of Sciences of the United States of America 117, 6640-6650, doi:10.1073/pnas.1921445117 (2020).
4. Wang XT., Liu TF., Zhang C., Gu YM., Cheng SW., Duan LQ., Zhang JH., Yin R., Zhao XJ., Shang M., Li YF., Ding A., Cheng TY., Wu SZ. & Gao, S. A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint. Nature Communications. 15(1):9114. doi: 10.1038/s41467-024-53561-2 (2024).
5. Wen Y., Yang X., Li Y., Zhao X., Ding A., Song D., Duan L., Cheng S., Zhu X., Peng B., Chang X., Zhang C., Yang F., Cheng T., Wang H., Zhang Y., Zhang T., Zheng S., Ren L*. & Gao S*. DRAIC mediates hnRNPA2B1 stability and m6A-modified IGF1R instability to inhibit tumor progression. Oncogene. 43 :2266-2278. doi: 10.1038/s41388-024-03071-8 (2024).
6. Peng B., Cheng S., Wang H., Liu T., Gu Y., Duan L., Cheng T., Wang X., Wang X., Zhang Q., Zhang Y., Zhao X., Yao X., Zhao X., Song D*., Zeng J*., Gao S*. N6-methyladenosine enhances the expression of TGF-β-SMAD signaling family to inhibit cell growth and promote cell metastasis. Cancer Letters 28, 217195, doi: 10.1016/j.canlet.2024.217195 (2024).
7. Jiang S., Han X., Liu T., He Y., Zhao Z., Liu T., Cheng S., Zhang J., Duan L., Liu Y., Cheng T., Liu Y., Ye Q., Gao S. HUNK inhibits cargo uptake and lysosomal traffic in the caveolar pathway via the AGAP3/ARF6. Science Bulletin (Beijing) 69, 173-178, doi: 10.1016/j.scib.2023.11.053 (2024).
8. Han, X., Jiang, S., Gu, Y., Ding, L., Zhao, E., Cao, D., Wang, X., Wen, Y., Pan, Y., Yan, X., Duan, L., Sun, M., Zhou, T., Liu, Y., Hu, H*., Ye, Q*. & Gao, S*. HUNK inhibits epithelial-mesenchymal transition of CRC via direct phosphorylation of GEF-H1 and activating RhoA/LIMK-1/CFL-1. Cell Death & Disease 14, 327, doi:10.1038/s41419-023-05849-2 (2023).
9. Zhu, Y., Liu, X., Wang, Y., Pan, Y., Han, X., Peng, B., Zhang, X., Niu, S., Wang, H., Ye, Q., Gu, Y*. & Gao, S*. DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma. Cell Death & Disease 13, 456, doi:10.1038/s41419-022-04898-3 (2022).
10. Gu, Y., Niu, S., Wang, Y., Duan, L., Pan, Y., Tong, Z., Zhang, X., Yang, Z., Peng, B., Wang, X., Han, X., Li, Y., Cheng, T., Liu, Y., Shang, L., Liu, T., Yang, X., Sun, M., Jiang, S., Zhang, C., Zhang, N., Ye, Q. & Gao, S. DMDRMR-Mediated Regulation of m(6)A-Modified CDK4 by m(6)A Reader IGF2BP3 Drives ccRCC Progression. Cancer Research 81, 923-934, doi:10.1158/0008-5472.Can-20-1619 (2021).
11. Jiang, S., Wang, X., Song, D., Liu, X., Gu, Y., Xu, Z., Wang, X., Zhang, X., Ye, Q., Tong, Z., Yan, B., Yu, J., Chen, Y., Sun, M., Wang, Y. & Gao, S. Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP. Cancer Research 79, 3063-3075, doi:10.1158/0008-5472.Can-18-3295 (2019).
